141064-23-5

中文名称诺美林草酸盐

英文名称 3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridineoxalate

CAS 141064-23-5

分子式 C14H23N3OS.C2H2O4

分子量 371

MOL 文件 141064-23-5.mol

更新日期 2024/11/15 18:20:32

141064-23-5 结构式

基本信息物理化学性质安全数据图谱信息诺美林草酸盐价格(试剂级) 常见问题列表

基本信息

中文别名

草酸占诺美林
诺美林草酸盐
呫诺美林草酸盐

英文别名

Lumeron
LY246708 oxalate
Xanomeline oxalate
Xanomeline oxalate salt
LY246708
MEMCOR
LUMERON
3-(3-Hexyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine oxalate
3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridineoxalate
3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridine ethanedioate (1:1)

物理化学性质

熔点148-150℃

储存条件Desiccate at +4°C

溶解度DMF: 1.6 mg/ml; DMF:PBS (pH 7.2) (1:9): 0.1 mg/ml

形态粉末

颜色White to off-white

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS06

警示词危险

危险性描述H301

防范说明P264-P270-P301+P310-P405-P501

图谱信息

诺美林草酸盐(141064-23-5)核磁图(¹HNMR)

诺美林草酸盐价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/05/22	HY-13410	诺美林草酸盐 Xanomeline oxalate	141064-23-5	5mg	450元
2025/05/22	HY-13410	诺美林草酸盐 Xanomeline oxalate	141064-23-5	10mg	710元
2025/05/22	HY-13410	诺美林草酸盐 Xanomeline oxalate	141064-23-5	25 mg	1313元

常见问题列表

生物活性

Xanomeline oxalate (LY246708 oxalate) 是一种有效的、选择性毒蕈碱受体激动剂 (SMRA)，可刺激体内的磷酸肌醇水解。 Xanomeline oxalate 可用于研究阿尔茨海默氏病。

靶点

muscarinic receptor

体外研究

Xanomeline stimulates phosphoinositide (PI) hydrolysis in the A9 L m1 cells.
Xanomeline inhibits [ ³ H]-pirenzepine ([ ³ H]-PZ) and [ ³ H]- oxotremorine -M ([ ³ H]-OXO-M) binding to rat brain with K _i s of 7 and 3 nM, respectively.

体内研究

Xanomeline robustly stimulates in vivo PI hydrolysis and the effect is blocked by muscarinic antagonists, demonstrating mediation by muscarinic receptors. In mice the ED ₁₀₀ for Xanomeline-induced stimulation of [ ³ H]-IP accumulation is 54 μmole/kg in hippocampus. And in rats the ED ₁₀₀ for Xanomeline-induced stimulation of [ ³ H]-IP accumulation is 8.1 μmole/kg in hippocampus.

Animal Model:	Male CF1 mice weighing 18-20 g are injected [ ³ H]-myoinositol
Dosage:	8.1-81 μmole/kg
Administration:	S.c. injections; 1 h prior to killing and 1 h after the administration
Result:	Increased accumulation in a dose-related manner up to 130%, 75%, 60% above lithium levels in hippocampus, cortex and neostriatum, respectively. And did not increase accumulation of [ ³ H]-IP in the brain stem. Induced salivation, tremor and hypothermia in mice with the ED ₅₀ of 13.7±0.8 μmole/kg.

Animal Model:	Rats are injected [ ³ H]-myoinositol
Dosage:	2.7-81 μmole/kg
Administration:	S.c. injections; 1 h prior to killing and 1 h after the administration
Result:	Increased [ ³ H]-IP formation dose dependently in hippocampus up to 221% above lithium control.